enzh-TWfrdeitjaptrues

Latest Bing Center News

Waldenstrom Patient Stories: Finding Strength

Waldenstrom Patient Stories: Finding Strength

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

Read more..

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

Read more..

IWMF Virtual Educational Forum - August 27-28, 2020

IWMF Virtual Educational Forum - August 27-28, 2020

As most of you know, the 2020 IWMF Educational Forum will be virtual/online and is coming soon (August 27-28) - see agenda and registration details at: https://www.iwmf.com/news-and-events/iwmf-educational-forum.

Read more..

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC (the Canadian affiliate of the IWMF) was proud to have Dr. Zachary Hunter of the Dana-Farber Cancer Institute join the Atlantic Canada WM Support Group for a recent virtual meeting. Dr Hunter described the latest research into Waldenstrom’s macroglobulinemia. After his talk, he took questions from the participants and described the latest research project he is taking on with the financial backing of the WMFC, IWMF, LLS and the Leukemia Foundation of Australia.

Read more..

New Waldenstrom Macroglobulinemia Patient Story of Hope

New Waldenstrom Macroglobulinemia Patient Story of Hope

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Read more..

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.

Read more..

IWMF Virtual Educational Forum August 27-28, 2020

IWMF Virtual Educational Forum August 27-28, 2020

Join us at the 2020 IWMF Virtual Educational Forum -  a unique opportunity to come together and learn from medical experts and WM community members around the world – all from the comfort of your own home! Experience our 2020 Vision: A World Without WM.

Read more..

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for the treatment of Waldenström macroglobulinemia (WM).

Read more..

The IWMF announces $800,000 in new research funding

The IWMF announces $800,000 in new research funding

The IWMF Board of Trustees has approved $800,000 in new research support for two research projects from the IWMF-LLS (Leukemia & Lymphoma Society) Strategic Research Roadmap initiative.

Read more..

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

After undergoing eighteen months of chemotherapy ending in 2014, which resulted in much success and years of being well managed and free of infusions, my WM flared up again, significantly, in 2019.  This required me to go back into treatment.

Read more..